| Parent Drug Name | Name of Impurity | Catalogue No. | |
|---|---|---|---|
| Regadenoson | 1-(6-Amino-9-β-D-ribofuranosyl-9H-purin-2-yl)-1H-pyrazole-4-carboxylic AcidEthyl Ester | VE009636 | View CAS 313348-16-2 |
| Regadenoson | 1-(6-Amino-9-β-D-ribofuranosyl-9H-purin-2-yl)-1H-pyrazole-4-carboxylic acid | VE009637 | View CAS 313348-29-7 |
| Regadenoson | 1-(6-Amino-9H-purin-2-yl)-N-methyl-1H-pyrazole-4-carboxamide | VE009634 | View CAS 1702334-23-3 |
| Regadenoson | 2-(1H-Pyrazol-1-yl)adenosine | VE009635 | View CAS 1627202-38-3 |
| Catalogue No. | VE009635 |
| CAS No. | 1627202-38-3 |
| Molecular Formula | C13H15N7O4 |
| Molecular Weight | 333.3 g/mol |
| Parent drug | Regadenoson |
| IUPAC Name | 2-(1H-Pyrazol-1-yl)adenosine |
| Synonyms | N/A |
| References | Sci-Hub, Regadenoson: A focused update. Journal of Nuclear Cardiology, 20(2), 284–288, 10.1007/s12350-012-9661-3. (2012). Retrieved June 14, 2022, from Sci-hub.se website: https://sci-hub.se/10.1007/s12350-012-9661-3 |
| Status | In-stock |
| ListName | 2-(1H-Pyrazol-1-yl)adenosine |
| Exclusively Supplied by Veeprho | Exclusively Supplied by Veeprho |
"*" indicates required fields
